S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:OPGN

OpGen (OPGN) Stock Price, News & Analysis

$0.70
-0.02 (-2.80%)
(As of 03/28/2024 ET)
Today's Range
$0.65
$0.75
50-Day Range
$0.26
$0.75
52-Week Range
$0.17
$3.84
Volume
1.58 million shs
Average Volume
4.53 million shs
Market Capitalization
$6.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

OpGen MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of OpGen in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.02) to ($0.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.06 out of 5 stars

OPGN stock logo

About OpGen Stock (NASDAQ:OPGN)

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

OPGN Stock Price History

OPGN Stock News Headlines

StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN)
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Dow Gains 100 Points; McCormick Posts Upbeat Results
Nasdaq Gains Over 50 Points; US Durable Goods Orders Rise In February
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
OpGen Investor David Lazar Is Named CEO
Opgen Inc
OpGen Inc OPGN
OpGen surges after announcing private placement
OpGen, Inc. (OPGN) interactive stock chart – Yahoo Finance
Why Is OpGen (OPGN) Stock Up 540% Today?
See More Headlines
Receive OPGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2023
Today
3/28/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:OPGN
Employees
85
Year Founded
N/A

Profitability

Net Income
$-37,280,000.00
Net Margins
-852.18%
Pretax Margin
-852.18%

Debt

Sales & Book Value

Annual Sales
$2.61 million
Book Value
$2.61 per share

Miscellaneous

Free Float
9,881,000
Market Cap
$6.96 million
Optionable
Not Optionable
Beta
-0.78
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives


OPGN Stock Analysis - Frequently Asked Questions

Should I buy or sell OpGen stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OPGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPGN, but not buy additional shares or sell existing shares.
View OPGN analyst ratings
or view top-rated stocks.

How have OPGN shares performed in 2024?

OpGen's stock was trading at $0.42 at the beginning of 2024. Since then, OPGN shares have increased by 65.5% and is now trading at $0.6950.
View the best growth stocks for 2024 here
.

Are investors shorting OpGen?

OpGen saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 20,800 shares, a decrease of 47.3% from the February 29th total of 39,500 shares. Based on an average trading volume of 1,470,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.2% of the company's shares are short sold.
View OpGen's Short Interest
.

When is OpGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our OPGN earnings forecast
.

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) issued its earnings results on Thursday, August, 10th. The medical research company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by $0.22. The medical research company earned $0.74 million during the quarter, compared to analysts' expectations of $0.90 million. OpGen had a negative trailing twelve-month return on equity of 316.30% and a negative net margin of 852.18%. During the same period last year, the firm posted ($2.60) EPS.

When did OpGen's stock split?

OpGen shares reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of OpGen own?
When did OpGen IPO?

OpGen (OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

How do I buy shares of OpGen?

Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPGN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners